BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 24884915)

  • 1. A large de novo 9p21.3 deletion in a girl affected by astrocytoma and multiple melanoma.
    Frigerio S; Disciglio V; Manoukian S; Peissel B; Della Torre G; Maurichi A; Collini P; Pasini B; Gotti G; Ferrari A; Rivoltini L; Massimino M; Rodolfo M
    BMC Med Genet; 2014 May; 15():59. PubMed ID: 24884915
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial melanoma-astrocytoma syndrome: synchronous diffuse astrocytoma and pleomorphic xanthoastrocytoma in a patient with germline CDKN2A/B deletion and a significant family history.
    Chan AK; Han SJ; Choy W; Beleford D; Aghi MK; Berger MS; Shieh JT; Bollen AW; Perry A; Phillips JJ; Butowski N; Solomon DA
    Clin Neuropathol; 2017; 36(5):213-221. PubMed ID: 28699883
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A germline deletion of p14(ARF) but not CDKN2A in a melanoma-neural system tumour syndrome family.
    Randerson-Moor JA; Harland M; Williams S; Cuthbert-Heavens D; Sheridan E; Aveyard J; Sibley K; Whitaker L; Knowles M; Bishop JN; Bishop DT
    Hum Mol Genet; 2001 Jan; 10(1):55-62. PubMed ID: 11136714
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of 9p21 deletions in UK melanoma families.
    Mistry SH; Taylor C; Randerson-Moor JA; Harland M; Turner F; Barrett JH; Whitaker L; Jenkins RB; Knowles MA; Bishop JA; Bishop DT
    Genes Chromosomes Cancer; 2005 Nov; 44(3):292-300. PubMed ID: 16032697
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States).
    Tran TP; Titus-Ernstoff L; Perry AE; Ernstoff MS; Newsham IF
    Cancer Causes Control; 2002 Sep; 13(7):675-82. PubMed ID: 12296515
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors.
    Bahuau M; Vidaud D; Jenkins RB; Bièche I; Kimmel DW; Assouline B; Smith JS; Alderete B; Cayuela JM; Harpey JP; Caille B; Vidaud M
    Cancer Res; 1998 Jun; 58(11):2298-303. PubMed ID: 9622062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Screening of germline mutations in the CDKN2A and CDKN2B genes in Swedish families with hereditary cutaneous melanoma.
    Platz A; Hansson J; Månsson-Brahme E; Lagerlof B; Linder S; Lundqvist E; Sevigny P; Inganäs M; Ringborg U
    J Natl Cancer Inst; 1997 May; 89(10):697-702. PubMed ID: 9168184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Deletion at chromosome arm 9p in relation to BRAF/NRAS mutations and prognostic significance for primary melanoma.
    Conway C; Beswick S; Elliott F; Chang YM; Randerson-Moor J; Harland M; Affleck P; Marsden J; Sanders DS; Boon A; Knowles MA; Bishop DT; Newton-Bishop JA
    Genes Chromosomes Cancer; 2010 May; 49(5):425-38. PubMed ID: 20140953
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The genetics of hereditary melanoma and nevi. 1998 update.
    Greene MH
    Cancer; 1999 Dec; 86(11 Suppl):2464-77. PubMed ID: 10630172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDKN2A/p16 is inactivated in most melanoma cell lines.
    Castellano M; Pollock PM; Walters MK; Sparrow LE; Down LM; Gabrielli BG; Parsons PG; Hayward NK
    Cancer Res; 1997 Nov; 57(21):4868-75. PubMed ID: 9354451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive analysis of CDKN2A (p16INK4A/p14ARF) and CDKN2B genes in 53 melanoma index cases considered to be at heightened risk of melanoma.
    Laud K; Marian C; Avril MF; Barrois M; Chompret A; Goldstein AM; Tucker MA; Clark PA; Peters G; Chaudru V; Demenais F; Spatz A; Smith MW; Lenoir GM; Bressac-de Paillerets B;
    J Med Genet; 2006 Jan; 43(1):39-47. PubMed ID: 15937071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 9p21.3 Microdeletion involving
    Jensen MR; Stoltze U; Hansen TVO; Bak M; Sehested A; Rechnitzer C; Mathiasen R; Scheie D; Larsen KB; Olsen TE; Muhic A; Skjøth-Rasmussen J; Rossing M; Schmiegelow K; Wadt K
    Cold Spring Harb Mol Case Stud; 2022 Jun; 8(4):. PubMed ID: 35422439
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Frequent loss of chromosome 9, homozygous CDKN2A/p14(ARF)/CDKN2B deletion and low TSC1 mRNA expression in pleomorphic xanthoastrocytomas.
    Weber RG; Hoischen A; Ehrler M; Zipper P; Kaulich K; Blaschke B; Becker AJ; Weber-Mangal S; Jauch A; Radlwimmer B; Schramm J; Wiestler OD; Lichter P; Reifenberger G
    Oncogene; 2007 Feb; 26(7):1088-97. PubMed ID: 16909113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family.
    Knappskog S; Geisler J; Arnesen T; Lillehaug JR; Lønning PE
    Genes Chromosomes Cancer; 2006 Dec; 45(12):1155-63. PubMed ID: 17001621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF.
    Pasmant E; Laurendeau I; Héron D; Vidaud M; Vidaud D; Bièche I
    Cancer Res; 2007 Apr; 67(8):3963-9. PubMed ID: 17440112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of 9p21 copy number alterations in human melanoma by fluorescence in situ hybridization.
    Rákosy Z; Vízkeleti L; Ecsedi S; Bégány A; Emri G; Adány R; Balázs M
    Cancer Genet Cytogenet; 2008 Apr; 182(2):116-21. PubMed ID: 18406873
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
    Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
    Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The contribution of large genomic deletions at the CDKN2A locus to the burden of familial melanoma.
    Lesueur F; de Lichy M; Barrois M; Durand G; Bombled J; Avril MF; Chompret A; Boitier F; Lenoir GM; ; Bressac-de Paillerets B; Baccard M; Bachollet B; Berthet P; Bonadona V; Bonnetblanc JM; Caron O; Chevrant-Breton J; Cuny JF; Dalle S; Delaunay M; Demange L; De Quatrebarbes J; Doré JF; Frénay M; Fricker JP; Gauthier-Villars M; Gesta P; Giraud S; Gorry P; Grange F; Green A; Huiart L; Janin N; Joly P; Kérob D; Lasset C; Leroux D; Limacher JM; Longy M; Mansard S; Marrou K; Martin-Denavit T; Mateus C; Maubec E; Olivier-Faivre L; Orlandini V; Pujol P; Sassolas B; Stoppa-Lyonnet D; Thomas L; Vabres P; Venat L; Wierzbicka E; Zattara H
    Br J Cancer; 2008 Jul; 99(2):364-70. PubMed ID: 18612309
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced detection of spitzoid melanomas using fluorescence in situ hybridization with 9p21 as an adjunctive probe.
    Gammon B; Beilfuss B; Guitart J; Gerami P
    Am J Surg Pathol; 2012 Jan; 36(1):81-8. PubMed ID: 21989344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of microsatellite alterations in the spectrum of melanocytic nevi in patients with or without individual or family history of melanoma.
    Birindelli S; Tragni G; Bartoli C; Ranzani GN; Rilke F; Pierotti MA; Pilotti S
    Int J Cancer; 2000 Apr; 86(2):255-61. PubMed ID: 10738254
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.